MedEA - Medical Education Academy

Today we will be speaking with Gabriela Brenta, Chief of the Thyroid Division of the Dr. Cesar Milstein Hospital and Assistant professor of the Medical School, University of Buenos Aires in Argentina.At the end of this podcast, learners should be able to appreciate the complexities of care post thyroid surgery and the need for personalised and long term treatment of patients, as well as understanding that maximising quality of life for patients with hypothyroidism is complex.This podcast is part of the continuing medical education programme entitled Hypothyroidism 2026 Importance of Personalised treatment targeting endocrinologists and other healthcare professionals involved in the diagnosis and management of thyroid disorders.

Hoy conversaremos con Gabriela Brenta, Jefa de la División de Tiroides del Hospital Dr. César Milstein y Profesora Adjunta de la Facultad de Medicina de la Universidad de Buenos Aires, Argentina.
Al finalizar este podcast, los oyentes podrán comprender la complejidad de la atención posterior a la cirugía de tiroides y la necesidad de un tratamiento personalizado y a largo plazo, así como la complejidad de optimizar la calidad de vida de los pacientes con hipotiroidismo.
Este podcast forma parte del programa de educación médica continua titulado «Hipotiroidismo 2026: Importancia del Tratamiento Personalizado», dirigido a endocrinólogos y otros profesionales de la salud involucrados en el diagnóstico y manejo de los trastornos tiroideos.

今天我们将与 Gabriela Brenta 教授进行对话。她是阿根廷布宜诺斯艾利斯 Dr. Cesar Milstein 医院甲状腺科主任，同时也是布宜诺斯艾利斯大学医学院的助理教授。在本播客结束时，学习者将能够理解甲状腺手术后护理的复杂性，并认识到对患者进行个体化、长期治疗的必要性，同时理解对于甲状腺功能减退症患者而言，全方位提升其生活质量是一个复杂的过程。本播客隶属于继续医学教育计划《2026 甲状腺功能减退症：个体化治疗的重要性》，面向内分泌科医生及其他从事甲状腺疾病诊断与管理的医护人员。

Today we will be speaking with Peter Clayton, Emeritus professor of Paediatric Endocrinology at the University of Manchester in the Uk.At the end of this podcast, learners should be able to describe pharmacogenomics and how it can impact the future care and management of patients with growth disorders.This podcast is part of the continuing medical education programme in entitled “Digital Decision Making in the Management of Growth Disorders 2026”, targeting clinicians, particularly paediatricians working in growth disorder management and those in general practise.Some content may be of interest also to specialist growth disorder nurses.

Hoy hablaremos con Peter Clayton, catedrático emérito de Endocrinología Pediátrica de la Universidad de Mánchester, en el Reino Unido.Al finalizar este pódcast, los participantes deberían ser capaces de describir la farmacogenómica y cómo puede influir en la atención y el tratamiento futuros de los pacientes con trastornos del crecimiento.Este pódcast forma parte del programa de formación médica continua titulado «Toma de decisiones digitales en el tratamiento de los trastornos del crecimiento 2026», dirigido a profesionales clínicos, en particular a pediatras especializados en el tratamiento de los trastornos del crecimiento y a médicos de atención primaria.Algunos contenidos también pueden ser de interés para el personal de enfermería especializado en trastornos del crecimiento.
 

오늘은 영국 맨체스터 대학교 소아 내분비학 명예교수인 피터 클레이튼 교수님과 이야기를 나눠보겠습니다.이 팟캐스트를 마치면, 학습자 여러분은 약물유전체학이 무엇인지, 그리고 이것이 성장 장애 환자의 향후 치료 및 관리에 어떤 영향을 미칠 수 있는지 설명할 수 있게 될 것입니다.이 팟캐스트는 '성장 장애 관리에서의 디지털 의사결정 2026'이라는 지속 의학교육 프로그램의 일부로 성장 장애 관리 분야의 임상의들, 특히 소아과 전문의 및 일반 진료 분야 종사자들을 대상으로 합니다.이번 내용 중에는 성장 장애를 전문으로 하는 간호사분들께도 도움이 될 만한 부분이 있습니다.

Today we will be speaking with Jacqueline Jonklaas, currently a Professor in the Endocrinology Division at Georgetown University in Washington D.C. as well as past President of the American Thyroid Association.
At the end of this podcast, learners should be able to address treatment expectations when initiating LT4 treatment and understand that maximising quality of life for patients with hypothyroidism is complex.
This podcast is part of the continuing medical education programme entitled “Hypothyroidism 2026: Importance of personalised treatment”, targeting endocrinologists and other healthcare professionals involved in the diagnosis and management of thyroid disorders

Hoy hablaremos con Jacqueline Jonklaas, actualmente profesora del departamento de Endocrinología de la Universidad de Georgetown en Washington D. C. y antigua presidenta de la Asociación Americana de Tiroides.
Al finalizar este pódcast, los oyentes deberían ser capaces de abordar las expectativas terapéuticas al iniciar el tratamiento con LT4 y comprender que maximizar la calidad de vida de los pacientes con hipotiroidismo es una tarea compleja.
Este pódcast forma parte del programa de educación médica continua «Hipotiroidismo 2026: la importancia del tratamiento personalizado», dirigido a endocrinólogos y otros profesionales sanitarios que participan en el diagnóstico y tratamiento de los trastornos tiroideos.

今天我们有幸专访 Jacqueline Jonklaas 教授。她现任华盛顿哥伦比亚特区乔治敦大学内分泌科教授，同时也曾担任美国甲状腺协会主席。
本期播客结束后，学习者应能做到以下两点，一是了解 LT4 初始治疗的预期疗效，二是认识到甲减患者生活质量的优化是一项复杂的工作。
本播客隶属于继续医学教育计划《2026 甲状腺功能减退症：个体化治疗的重要性》，面向内分泌科医生及其他从事甲状腺疾病诊断与管理的医护人员

Today we will be speaking with Sandro Loche, senior researcher at the Bambino Gesu Children's Hospital in Rome.
At the end of this podcast, learners should be able to evaluate the role of AI and other technological advances in enhancing clinical care of patients with short stature, as well as appreciate that digital technology can improve patient adherence to recombinant human growth hormone.
This podcast is part of the continuing medical education programme entitled “Digital Decision Making in the Management of Growth Disorders 2026”, targeting clinicians, particularly paediatricians working in growth disorder management and those in general practise.
Some content may be of interest also to specialist growth disorder nurses